Type 2 diabetes mellitus (T2DM) is characterized by a progressive failure of pancreatic β-
cell function (BCF) with insulin resistance. Once insulin over-secretion can no longer …

Metformin is now established as a first-line antidiabetic therapy for the management of type
2 diabetes. Its early use in treatment algorithms is supported by lack of weight gain, low risk …

Multiple Imputation and its Application The most up-to-date edition of a bestselling guide to
analyzing partially observed data In this comprehensively revised Second Edition of Multiple …

Insulin resistance in muscle and liver and-cell failure represent the core pathophysiologic
defects in type 2 diabetes. It now is recognized that the-cell failure occurs much earlier and …

Description: The American College of Physicians (ACP) developed this guideline to present
the evidence and provide clinical recommendations on oral pharmacologic treatment of type …

Two general approaches to the treatment of type 2 diabetes mellitus (T2DM) have been
advocated. 1) A “guideline” approach that advocates sequential addition of antidiabetes …

Background Rosiglitazone is an insulin sensitiser used in combination with metformin, a
sulfonylurea, or both, for lowering blood glucose in people with type 2 diabetes. We …

Background A recent meta-analysis raised concern regarding an increased risk of
myocardial infarction and death from cardiovascular causes associated with rosiglitazone …

This article has been corrected. The original version (PDF) is appended to this article as a
supplement. Description: The American College of Physicians (ACP) developed this …

Aims Thiazolidinediones are insulin sensitizers, and are associated with fluid retention and
increased risk of heart failure (HF) in people with type 2 diabetes. We assessed fatal and …